Ensituximab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Ensituximab Usage And Synthesis

Uses

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2].

References

[1] Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. DOI:10.1158/1078-0432.CCR-20-0426
[2] Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8. DOI:10.1186/s13045-017-0552-6

Ensituximab(1092658-06-4)Related Product Information

• Stamulumab
• Etaracizumab
• palivizumab
• Dacetuzumab
• Semorinemab
• Pivekimab
• Anvatabart
• Uliledlimab
• Obinutuzumab
• Omburtamab